New treatment targets for the management of irritable bowel syndrome

作者：Rao Supriya^*; Weber H Christian

来源：Current Opinion in Endocrinology Diabetes and Obesity, 2014, 21(1): 9-14.

DOI：10.1097/MED.0000000000000034

• chronic idiopathic constipation
• gastrointestinal receptors
• irritable bowel syndrome (IBS)
• linaclotide
• lubiprostone
• serotonin

Purpose of reviewIrritable bowel syndrome (IBS) and chronic idiopathic constipation (CIC) are highly prevalent medical conditions that reduce quality of life and represent a substantial economic burden on healthcare cost. Until recently, no specific treatment options were available. This review will provide an update of the most recent randomized clinical trials data showing efficacy and safety of novel, targeted treatment modalities in IBS and CIC with gastrointestinal receptor and ion channel agonists.Recent findingsRecent discoveries of peptides and small molecules targeting gastrointestinal receptors and ion channels resulted in novel, specific pharmacological therapies of IBS and CIC. The bicyclical fatty acid lubiprostone and the synthetic 14-amino acid peptide linaclotide were identified to selectively activate a Chloride Channel-2 and the Guanylin Cyclase-C receptor, respectively, and demonstrate efficacy in the treatment of IBS with constipation and CIC.SummaryNovel molecules including the bicyclical fatty acid lubiprostone and the synthetic 14-amino acid peptide linaclotide represent new treatment modalities for IBS with constipation and CIC with proven efficacy and acceptable side-effect profiles.

• 出版日期2014-2